<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00742495</url>
  </required_header>
  <id_info>
    <org_study_id>BCX1777-108</org_study_id>
    <secondary_id>2008-00221942</secondary_id>
    <nct_id>NCT00742495</nct_id>
  </id_info>
  <brief_title>Pharmacokinetic Study of Forodesine in Children With Relapsed or Refractory T-cell or B-cell Precursor Acute Lymphoblastic Leukaemia or T-cell Non- Hodgkin's Lymphoma.</brief_title>
  <acronym>BCX1777-108</acronym>
  <official_title>A Phase I/II Pharmacokinetic Study of Intravenous and Oral Forodesine in Children With Relapsed or Refractory T-cell or B-cell Precursor Acute Lymphoblastic Leukaemia or T-cell Non-Hodgkin's Lymphoma.</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Mundipharma Research Limited</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Innovative Therapies For Children with Cancer Consortium</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>Mundipharma Research Limited</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of this study is to evaluate the pharmacokinetics, pharmacodynamics and safety of&#xD;
      different doses of intravenous and oral Forodesine in children with relapsed or refractory&#xD;
      T-cell or B-cell precursor Acute Lymphoblastic Leukaemia or T-cell Non-Hodgkin's Lymphoma.&#xD;
      Preliminary efficacy will also be assessed.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      A multi-centre, multi-national, open label trial of Forodesine in children with relapsed or&#xD;
      refractory T-cell or B-cell precursor Acute Lymphoblastic Leukaemia or T-cell Non-Hodgkin's&#xD;
      Lymphoma. The primary objective of the study is to evaluate the pharmacokinetics and&#xD;
      pharmacodynamics of six different dose schedules of Forodesine. Secondary objectives are to&#xD;
      evaluate safety and to collect preliminary efficacy data. All patients will receive active&#xD;
      drug. The Initial Treatment Phase will last 37 days with a final response assessment on Day&#xD;
      37. Patients who achieve a response may be eligible to receive extended treatment with&#xD;
      Forodesine for up to 6 months.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Terminated</overall_status>
  <why_stopped>
    Slow Recruitment&#xD;
  </why_stopped>
  <start_date>March 2009</start_date>
  <completion_date type="Actual">September 2010</completion_date>
  <primary_completion_date type="Actual">September 2010</primary_completion_date>
  <phase>Phase 1/Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Pharmacokinetics and pharmacodynamics - data will be collected on Day 1, 5, 8 and 36.</measure>
    <time_frame>Day 1, and 36</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Safety data will be collected throughout the study. Efficacy will be assessed on Day 15 and Day 37.</measure>
    <time_frame>Day 15 and 37</time_frame>
  </secondary_outcome>
  <enrollment type="Actual">2</enrollment>
  <condition>Relapsed or Refractory T-cell Acute Lymphoblastic Leukaemia</condition>
  <condition>B-cell Precursor Acute Lymphoblastic Leukaemia</condition>
  <condition>T-cell Non-Hodgkin's Lymphoma</condition>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Forodesine</intervention_name>
    <description>PK study</description>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Males and females aged ≥ 2 years to ≤18 years. ≥ 13 kg&#xD;
&#xD;
          -  Female subjects of childbearing potential (i.e. have reached the age of menarche) must&#xD;
             have a negative serum or urine pregnancy test recorded prior to the first dose of&#xD;
             study medication, be non-lactating, and be willing to use adequate and highly&#xD;
             effective method of contraception throughout the study and for one month after the&#xD;
             last dose of study medication, if sexually active.&#xD;
&#xD;
          -  Sexually active male subjects must be willing and able to use a barrier form of&#xD;
             contraception (i.e. condoms) or sexual abstinence throughout the study and for one&#xD;
             month after the last dose of study medication&#xD;
&#xD;
          -  Unequivocal histological diagnosis of T-ALL, BCP-ALL or T-NHL (World Health&#xD;
             Organisation [WHO] classification) at initial diagnosis&#xD;
&#xD;
          -  Relapse (³25% marrow blasts) or failure to respond after at least one standard regimen&#xD;
             for their disease for subjects with a T-cell malignancy who are ineligible for other&#xD;
             therapy of greater curative potential, or failure to respond after at least two&#xD;
             standard regimens for subjects with a B-cell precursor malignancy&#xD;
&#xD;
          -  KPS or LPS (as appropriate for subject's age) scores ³60&#xD;
&#xD;
          -  Anticipated life expectancy of at least 6 weeks&#xD;
&#xD;
          -  Adequate kidney (creatinine levels ≤ 2.0 times upper limit of normal) and liver&#xD;
             function tests (aspartate aminotransferase [AST] and/or alanine aminotransferase [ALT]&#xD;
             ≤3 times upper limit of normal and total bilirubin ≤5 times upper limit of normal)&#xD;
&#xD;
          -  Signed ICF and assent if appropriate according to local laws and regulations prior to&#xD;
             start of any study specific procedures.&#xD;
&#xD;
        Exclusion criteria:&#xD;
&#xD;
          -  Females who are pregnant (positive β-hCG test) or lactating&#xD;
&#xD;
          -  Subjects with a history of HIV and/or HTLV-1&#xD;
&#xD;
          -  Subjects with known active HBV, HCV, CMV and/or EBV infection&#xD;
&#xD;
          -  Subjects with clinical evidence of active symptomatic CNS disease&#xD;
&#xD;
          -  Subjects with active serious infection&#xD;
&#xD;
          -  Prior treatment with any antileukemic agent, chemotherapy or leukophoresis treatment&#xD;
             within 7 days (within 4-5 days for 6-mercaptopurine (MP) and within 2 days for&#xD;
             low-dose methotrexate) prior to study entry&#xD;
&#xD;
          -  Lack of full recovery from adverse drug reactions due to prior therapy, independent of&#xD;
             when that therapy was given&#xD;
&#xD;
          -  Concurrent treatment with other anticancer agents (CNS prophylaxis e.g. intrathecal&#xD;
             methotrexate and corticosteroid use will not be excluded)&#xD;
&#xD;
          -  Subjects who have chronic gastrointestinal disease or conditions that may hamper&#xD;
             compliance and/or absorption of the product; however, study drug administration via&#xD;
             nasogastric or gastrostomy tube is allowed&#xD;
&#xD;
          -  Any history of hypersensitivity or intolerance to any component of the study&#xD;
             medication.&#xD;
&#xD;
          -  Subjects who have received an investigational medicinal product within 30 days of&#xD;
             study entry (defined as the start of the Screening Period).&#xD;
&#xD;
          -  Current participation in another clinical trial is not permitted unless the sole&#xD;
             purpose of the trial is for long term follow up/survival data.&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>2 Years</minimum_age>
    <maximum_age>18 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <location>
    <facility>
      <address>
        <city>Vienna</city>
        <country>Austria</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Prague</city>
        <country>Czech Republic</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Prof Gerard Michel</name>
      <address>
        <city>Marseilles</city>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Charite Universitymedicine</name>
      <address>
        <city>Berlin</city>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Dr Giovanna Gioriani</name>
      <address>
        <city>Pavia</city>
        <country>Italy</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Sally Kinsey</name>
      <address>
        <city>Leeds</city>
        <country>United Kingdom</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Austria</country>
    <country>Czech Republic</country>
    <country>France</country>
    <country>Germany</country>
    <country>Italy</country>
    <country>United Kingdom</country>
  </location_countries>
  <removed_countries>
    <country>Netherlands</country>
  </removed_countries>
  <verification_date>February 2012</verification_date>
  <study_first_submitted>August 26, 2008</study_first_submitted>
  <study_first_submitted_qc>August 26, 2008</study_first_submitted_qc>
  <study_first_posted type="Estimate">August 27, 2008</study_first_posted>
  <last_update_submitted>October 23, 2012</last_update_submitted>
  <last_update_submitted_qc>October 23, 2012</last_update_submitted_qc>
  <last_update_posted type="Estimate">October 24, 2012</last_update_posted>
  <responsible_party>
    <name_title>Mundipharma Research Ltd</name_title>
    <organization>Mundipharma Research Ltd</organization>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Lymphoma</mesh_term>
    <mesh_term>Leukemia</mesh_term>
    <mesh_term>Lymphoma, Non-Hodgkin</mesh_term>
    <mesh_term>Precursor Cell Lymphoblastic Leukemia-Lymphoma</mesh_term>
    <mesh_term>Leukemia, Lymphoid</mesh_term>
    <mesh_term>Lymphoma, T-Cell</mesh_term>
    <mesh_term>Precursor T-Cell Lymphoblastic Leukemia-Lymphoma</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

